Opinion|Videos|July 10, 2024
ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management
Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs nivolumab in patients with previously untreated metastatic or unresectable melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study.
- How might these findings impact the management of patients with metastatic melanoma?
- The study examined melanoma-specific survival (MSS) outcomes. What is the significance of sustained improvement in MSS observed with nivolumab plus relatlimab?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
2
TrumpRx Launch Brings Savings—and Uncertainty
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
5
